Treatment of venous thromboembolism in elderly patients in the era of direct oral anticoagulants

Authors: Tobias Tritschler, Lana A. Castellucci, Nick Van Es, Drahomir Aujesky, Grégoire Le Gal

Article type: Review article

Received: February 27, 2020.

Accepted: February 27, 2020.

Published online: March 3, 2020.

ISSN: 1897-9483

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA4.0), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only. For commercial use, please contact the journal office at pamw@mp.pl.
Treatment of venous thromboembolism in elderly patients in the era of direct oral anticoagulants

AUTHORS
Tobias Tritschler¹,², Lana A. Castellucci², Nick Van Es³, Drahomir Aujesky¹, Grégoire Le Gal²

AFFILIATIONS
1 Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland;
2 Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada.
3 Department of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

SHORT TITLE
DOACs for treatment of VTE in the elderly

CORRESPONDING AUTHOR
Tobias Tritschler, Department of General Internal Medicine, Inselspital, Bern University Hospital, Freiburgstrasse 18, 3010 Bern, Switzerland; phone number: (+41) 031 632 21 11; e-mail address: tobias.tritschler@insel.ch

CONFLICT OF INTEREST
Tobias Tritschler reports having received travel and congress fees from Pfizer.
ABSTRACT

The incidence of venous thromboembolism (VTE) and VTE-related morbidity and mortality increase with advancing age. Over the past decade, substantial advances in treatment of VTE have been made, most notably the introduction of direct oral anticoagulants (DOACs) which offer simple treatment regimens across a broad spectrum of VTE patients and have become the first-choice anticoagulants in many VTE patients. Even though elderly patients are underrepresented in clinical trials, extrapolation of overall study results to the elderly subpopulation appears justified for acute VTE treatment and for the choice of anticoagulant agent. In the elderly, DOACs are not only associated with a lower risk of bleeding but they even appear to be more efficacious than vitamin K antagonists in preventing recurrent VTE during the acute treatment period. The most challenging aspect of VTE management in elderly patients is determination of optimal treatment duration. The risk of bleeding increases with advancing age but also several risk factors for recurrent VTE after stopping anticoagulation are more frequent in the elderly. Clinical decision rules estimating risk of recurrent VTE and bleeding have limited utility in elderly patients. Shared decision making considering patient preferences and values is therefore crucial to help determine individual treatment duration in elderly patients.

KEY WORDS

Direct oral anticoagulants; Elderly; Pulmonary embolism; Treatment; Venous thromboembolism.
INTRODUCTION

Venous thromboembolism (VTE), defined as pulmonary embolism (PE) or deep vein thrombosis (DVT), is a common disease in the elderly population. The incidence of VTE increases exponentially with age and is 4-12 per 1000 person-years in persons aged 80 years and older, which reflects a 5 to 10-fold higher risk of developing VTE compared to persons aged 40 to 50 years [1]. While the incidence of DVT has remained stable or even decreased over time [2, 3], the incidence of PE has increased in both the younger and the elderly population in recent decades [3]. The latter is partly related to the widespread use of sensitive multi-detector computed tomography pulmonary angiography resulting in more frequent diagnosis of smaller, potentially insignificant PE than the use of single-detector computed tomography or ventilation-perfusion scan [4-6]. Not only the incidence of VTE but also clinical presentation, prognostic factors, and outcome rates differ between younger and older patients with acute VTE [7, 8]. Furthermore, evidence regarding optimal treatment of VTE in the elderly including first-choice anticoagulant agent and duration of anticoagulation is limited because elderly patients were underrepresented in clinical trials [7, 9]. As a consequence, the 2016 American College of Chest Physician (ACCP) and the 2019 European Society of Cardiology guidelines do not make specific recommendations for elderly patients, but only acknowledge the higher risk of bleeding in this population [10, 11].

Over the past decade, substantial advances in treatment of VTE have been made [12], most notably the introduction of direct oral anticoagulant (DOACs) which offer simple treatment regimens across a broad spectrum of VTE patients. In light of the significant proportion of elderly among patients with VTE and their distinct risk of VTE-related outcomes, in this review, we summarize evidence of VTE treatment with DOACs
in elderly patients and we discuss situations in which other anticoagulants may be preferred.

DEFINITION OF THE ELDERLY AND ANALYSES FOR THIS REVIEW

The US Census Bureau defines the elderly as the population aged 65 years and older; most other developed countries have accepted similar definitions. Definitions for the elderly in studies in the field of VTE are more heterogenous. Subgroup analyses of many recent pivotal randomized controlled trials used age 75 years as cut-off; in recent cohort studies cut-offs ranged from 60 to 80 years. In this review, we will report results using the definition of the pertinent reference.

Amongst previously published evidence, we will also report pooled risk ratios of phase III DOAC trials for VTE treatment by age. Relative risks with corresponding 95% confidence intervals (CI) were calculated based on crude event numbers reported in the trial publications in which the intention-to-treat population was used for efficacy outcomes and the safety population for bleeding outcomes. If not available in the original publication, event numbers were extracted from a meta-analysis that published subgroup analyses based on additional information from the corresponding authors and sponsors of the study [13]. Pooled relative risks were calculated using the Mantel-Haenszel method. The between-study variance was estimated using the DerSimonian-Laird method, and heterogeneity reported with the $I^2$ statistic. All analyses were performed in R, version 3.6.1 [14], by using the meta package, version 4.9-7 [15].
PHARMACOKINETICS AND PHARMACODYNAMICS OF DIRECT ORAL ANTICOAGULANTS

DOACs specifically target single steps in the coagulation pathway by direct inhibition of activated factor X (rivaroxaban, apixaban, and edoxaban) or thrombin (dabigatran). Rivaroxaban at doses of 15 or 20 mg daily requires to be taken with food as this increases its bioavailability (66% without food; 80-100% with food), which is not required for other DOACs [16]. Dabigatran is a pro-drug and it should not be crushed before ingestion as this results in a 75% increase of its bioavailability [16]. Rivaroxaban, apixaban, and edoxaban can be administered in crushed form if patients are unable to swallow tablets [17-19]. DOACs have a dual mode of elimination consisting of hepatic metabolism and renal excretion at different degrees depending on drug. The proportion of renal clearance to non-renal clearance of the absorbed DOAC is 27% for apixaban, 35% for rivaroxaban, 50% for edoxaban, and 80% for dabigatran [16]. Elimination half-lives in persons with normal kidney function range from 5-9 hours (rivaroxaban) to 12-17 hours (dabigatran). DOAC exposure increases with age but this association is confounded by the influence of age on the kidney function. For instance, the area under the concentration-time curve for a single dose of rivaroxaban 10 mg increased in average by 41% in healthy elderly persons (weighted mean age 77 years) compared to younger persons (weighted mean age 32 years) which was, however, at least partially explained by the lower creatinine clearance in the elderly persons (weighted mean clearance 55 mL/min versus 121 mL/min) [20]. Similarly, point estimates of edoxaban trough levels in patients with atrial fibrillation were higher in the elderly, irrespective of dose regimen [21], and edoxaban trough concentrations in patients on edoxaban 60 mg daily for atrial fibrillation showed an inverse relationship to
kidney function [22]. Despite being higher on average, DOAC exposure and trough levels in the elderly were within the observed interindvidual variability of the overall study populations [20, 21, 23-26]. Accordingly, dose adjustment based on age was not required in any of the phase III DOAC trials for VTE treatment. Of note, the product monograph of dabigatran recommends adjusting the dose of dabigatran to 110 mg twice daily for VTE treatment in patients aged 80 years and older, and in those aged 75 years and older with one or more risk factors for bleeding. Dabigatran at 110 mg twice daily has not been assessed for VTE treatment in a clinical trial, but the recommended dose reduction might be justified by results from the pooled analysis of phase III trials for treatment of acute VTE which showed that the bleeding risk reduction with dabigatran was influenced by age. Compared to vitamin K antagonists (VKAs), dabigatran was associated with a reduced risk of bleeding in younger patients but this effect was inverse in patients above 85 years in whom VKAs were associated with a lower risk of bleeding than dabigatran [27].

DOACs have fewer food and drug interactions compared with VKAs; still, such interactions have to be considered before prescribing a DOAC [16]. This is particularly important in elderly patients since number of medications and co-morbidities increase with age. The most relevant drug-drug interactions leading to clinically significant alteration in DOAC plasma levels concern drugs metabolized by cytochrome P450 3A4 in patients on apixaban and rivaroxaban or potent P-glycoprotein inhibitors in patients on any DOAC. There are no studies indicating that drug-drug interactions differ between elderly and younger patients, but there is insufficient evidence to draw any firm conclusions [28].
In essence, predictable pharmacodynamics and pharmacokinetics allow for a fixed-dose regimen across all patients eligible for DOAC treatment. Edoxaban is the only DOAC for acute VTE treatment requiring dose adjustment in certain circumstances including any one of: impairment of kidney function (i.e., creatinine clearance of 30-50 mL/min), body weight below 60 kg, and concomitant treatment with potent P-glycoprotein inhibitors. Whether the dose adjustment of dabigatran in elderly patients as recommended in the product monograph is appropriate for treatment of acute VTE has not been evaluated in a clinical trial but may be justified by a secondary analysis of the RE-COVER trials. On the other hand, inappropriate dose reduction of DOACs during initial and long-term VTE treatment occurs more frequently in elderly patients and is associated with an increased risk of recurrent VTE [29].

**TREATMENT OF ACUTE VENOUS THROMBOEMBOLISM**

The choice of treatment for acute VTE depends on clinical presentation, site of VTE, and benefits and risks of anticoagulation, which should be carefully weighed when determining the optimal therapeutic approach.

**Thrombolysis**

Hypotension is associated with increased short-term mortality in patients with acute PE [30, 31]. Guidelines recommend systemic thrombolysis in such patients to achieve rapid improvement of pulmonary obstruction and subsequent reduction of the risk of PE-related death [10, 11]. This benefit comes at the cost of an increased risk of bleeding, which is higher in patients above 75 years than in younger patients (13% vs 3% for major bleeding; 1.4% vs 0.5% for intracranial bleeding) [32, 33]. The 2016 ACCP
guidelines therefore specify that age over 75 years is a relative contraindication to thrombolysis while the 2019 ESC guidelines do not make age-specific recommendations [10, 11]. Data from the Nationwide Inpatient Sample between 1999 and 2008 indicate that unstable elderly patients are less likely to undergo systemic thrombolysis than younger patients regardless of presence of co-morbidities [34]. Whether this represents undertreatment or appropriate withholding of systemic thrombolysis due to an unacceptably high bleeding risk remains to be determined.

In normotensive PE patients, primary thrombolysis is not recommended in any age group [10, 11]. The PEITHO trial randomized hemodynamically stable PE patients with increased troponin and right ventricular dysfunction on imaging to systemic thrombolysis plus heparin or placebo plus heparin [35]. The risk of death or hemodynamic deterioration in patients over 75 years was similar between thrombolysis and placebo (4.3% vs 6.7%), but thrombolysis was associated with an increased risk of major bleeding (11.1% vs 0.6%) [35]. Preliminary evidence indicates that bleeding risk could be mitigated by reduced-dose or catheter-directed thrombolysis,[36, 37] but methodologically rigorous trials are required before such treatment can be recommended.

In patient with iliofemoral DVT, catheter-directed thrombolysis in addition to anticoagulation reduced the risk of post-thrombotic syndrome at 2 and 5 years of follow-up in the CAVENT trial [38, 39]. These results were not confirmed in two recent trials [40, 41]. The ATTRACT trial which randomized 692 patients with a proximal DVT to receive pharmacomechanical thrombolysis (i.e., catheter-directed lysis, mechanical thrombus removal, or both) plus anticoagulation or anticoagulation alone, showed no difference between the treatment arms with regard to occurrence of recurrent VTE,
mortality, post-thrombotic syndrome, and quality of life between 6 and 24 months after diagnosis [40]. Similar results were seen in the smaller CAVA trial [41]. The lack of efficacy and moreover, the increased risk of major bleeding with the addition of catheter-directed thrombolysis to anticoagulation (3.3% vs. 0%, 1.7% vs. 0.3%, and 5% vs. 0% in the CAVENT, ATTRACT and CAVA trial, respectively) [38, 40, 41], support current guideline recommendations to consider thrombolysis only if the limb is threatened [10]. Given the increased risk of bleeding in elderly patients, this conservative approach can likely be extrapolated to patients aged over 75 years who were excluded from the CAVENT and ATTRACT trial and underrepresented in the CAVA trial (median age, 52 years; interquartile range, 38-67 years).

**Oral anticoagulants for acute treatment**

In normotensive patients with VTE, anticoagulation is the mainstay of treatment. The choice of the optimal anticoagulant agent mainly depends on VTE etiology, kidney function, and co-medications. In patients without cancer or severe kidney disease, DOACs are the first-choice anticoagulant [10, 11]. Since there are no head-to-head DOAC trials, one DOAC cannot be recommended over another [42]. DOACs for acute VTE treatment have been compared to VKA therapy in six phase 3 trials using a non-inferiority study design. The proportion of participants over 75 years ranged from 10% to 15% across these studies (Table 1), indicating underrepresentation of the elderly population as epidemiologic studies show this age group represents approximately 25% of the VTE population [43]. While the overall risk of recurrent VTE did not differ between elderly and younger patients, concerns of a higher risk of bleeding in elderly patients were confirmed in the DOAC trials; there was an almost 3-fold higher risk of major
bleeding in patients aged over 75 years compared to younger patients, irrespective of treatment allocation (Figures 1A and 2A). In patients over 75 years, the risk of recurrent VTE was consistently lower in patients on a DOAC compared to those on a VKA with a pooled overall relative risk reduction of 44% (95% confidence interval [CI], 0.38-0.82; I², 0%; Figure 1B) [13]. This risk reduction was not seen in younger patients (risk ratio, 0.99; 95% CI, 0.85-1.17; I², 0%). Similar to younger patients, DOACs were associated with a lower risk of major bleeding than VKAs in elderly patients (risk ratio, 0.51; 95% CI, 0.30-0.85; I², 60%; Figure 2B) [13]. In summary, the risk of bleeding increased with age for both VKAs and DOACs, but DOACs were associated with a lower risk of bleeding compared with VKAs. Subgroup analyses of the Hokusai-VTE trial also indicated that efficacy of edoxaban as well as its lower risk of bleeding compared to VKA therapy was preserved in elderly patients with multimorbidity and polypharmacy [44]. In a large US claims database study, frail patients, defined as per the Johns Hopkins Claims-Based Frailty Indicator score, were less likely to experience recurrent VTE on rivaroxaban than on a VKA with no difference in the risk of bleeding [45]. Post-marketing phase IV trials and DOAC registries confirmed that DOACs are safe and effective alternatives to VKAs for treatment of VTE in routine clinical practice [46]. Interestingly, the mean age of patients enrolled in those studies (range 56-62 years) was similar to that of patients enrolled in the large phase III randomized controlled trials (range 55-58 years) [27, 46-51].

In cancer patients, the choice of anticoagulant agent is less obvious and should be individualized incorporating patient preferences and values, cancer type, additional risk factors for bleeding, and co-medications [52]. In recent randomized controlled trials, DOACs for treatment of cancer-associated VTE were associated with a higher risk of
bleeding (risk ratio, 1.74; 95% CI, 1.05-2.88) and possibly a lower risk of recurrent VTE (risk ratio, 0.65; 95% CI, 0.42-1.01) compared to treatment with low-molecular-weight heparin [53]. The Hokusai-VTE cancer study is the only randomized controlled trial assessing DOACs versus low-molecular-weight heparin for cancer-associated VTE which reported results on the subgroup of patients by age (<65 versus ≥65 years, and <75 years versus ≥75 years) [54]. The primary composite outcome of recurrent VTE or major bleeding did not differ by age [54]. Similar to the findings in the entire study cohort, in patients aged 65 years or older, the risk of recurrent VTE appeared to be lower (6.9% vs 9.9%) and the risk of major bleeding (8.0% vs 4.2%) to be higher with edoxaban than with dalteparin [54].

Given that DOAC clearance depends on renal function, patients with severe renal failure (i.e., creatine clearance <25-30 mL/min) have been excluded from phase III DOAC trials. Therefore, VKAs remain the anticoagulants of choice in these patients. Although chronic kidney disease becomes more prevalent with increasing age, severe renal failure remains relatively rare in the general elderly population as 3.2% of persons aged 75 years or older have an estimated glomerular filtration rate below 30 mL/min [55, 56]. Retrospective data suggest that apixaban may be associated with lower risks of bleeding, thromboembolic events, and mortality compared to VKAs in patients with atrial fibrillation and end stage kidney disease [57]. Whether these benefits hold true for treatment of VTE in a randomized study is uncertain. Results of the ongoing VERDICT study (ClinicalTrials.gov identifier: NCT02664155) will address whether reduced doses of apixaban and rivaroxaban for treatment of VTE in patients with moderate to severe kidney disease (i.e., 15-50 mL/min) are non-inferior to standard of care (i.e., parenteral anticoagulant plus a VKA). While awaiting more data in patients with severe kidney
disease, we consider DOACs efficacious and safe in patients with non-severe kidney disease. Even though the risk of bleeding increases with declining kidney function, DOACs were associated with a lower risk of bleeding than VKAs in patients with non-severe kidney disease without a difference in treatment efficacy [13, 58].

EXTENDED TREATMENT OF VENOUS THROMBOEMBOLISM

Duration of treatment

Once the acute phase of VTE treatment (i.e., first 3 months after diagnosis) is completed, determination of whether to continue or stop anticoagulation is based on balancing the risks of bleeding and recurrent VTE on and off anticoagulant treatment, including associated case-fatality rates. The risk of recurrent VTE is mainly determined by the etiology of VTE. Patients with a strong, transient provoking factor (e.g. major surgery) are at low risk of recurrence and treatment should be stopped after 3 months [10]. Patients with unprovoked VTE are at high risk of recurrence and continuing treatment is recommended, unless the risk of bleeding is high [10]. Continuing treatment reduces the risk of recurrent VTE by 80-90% while patients are on anticoagulants but does not reduce the risk of recurrence once therapy is discontinued [59]. Whether the risk of a recurrent VTE after stopping anticoagulation is higher in the elderly remains controversial [60-68]. In contrast, the risk of major bleeding was consistently shown to be about 2 to 3-fold higher in patients aged above 75 years regardless of anticoagulant drug used (Figure 2A) [13, 63, 69]. Similarly, patients with VTE in the context of active cancer are at high risk of recurrence and as such, extended treatment is recommended for cancer-associated VTE, unless the risk of bleeding outweighs the benefit of anticoagulation [10]. This recommendation is mainly based on expert opinion, given that
only few prospective studies have assessed extended anticoagulant treatment in cancer patients [70-74]. There is only one randomized controlled trial that aimed to assess anticoagulation versus placebo for extended treatment of cancer-associated VTE but it was prematurely terminated due to slow recruitment [74].

Although the risk of recurrence after stopping anticoagulation is overall high in patients with a first unprovoked VTE (10% in the first year, 25% at 5 years, and 36% at 10 years) [75], efforts have been made to identify a subgroup of patients with a low enough risk to justify stopping anticoagulation after 3-6 months. Because the risk of bleeding and possibly the risk of recurrent VTE increase with age, it is uncertain whether the generally recommended threshold of an acceptable recurrence risk of 5% in the first year after stopping treatment can be applied in the elderly population [76]. Four clinical decision rules (HERDOO2, Vienna Prediction Model, DASH, PIT-STOP) have been developed to help clinicians determine the risk of recurrence after a first unprovoked VTE [65-67, 77]. The only rule which has been validated in a management study is the HERDOO2 rule. It allows to identify women at low risk of recurrence based on age, D-dimer levels, signs of post-thrombotic syndrome, and body mass index [78]. Subgroup analyses of the study, however, indicated that among women classified as low-risk, the risk of recurrence was substantially higher in women above 50 years (5.7 events per 100 patient-years) than in women below 50 years (2.0 events per 100 patient-years) [78]. Furthermore, the proportion of patients identified at low risk of recurrence is smaller in the elderly given that not only age 65 years or older but also other score criteria are more frequent in the elderly: advanced age is a risk factor for post-thrombotic syndrome [79, 80] and normal D-dimer values are rare in elderly patients with an unprovoked VTE [81]. In elderly patients, both the Vienna Prediction Model and the DASH score showed
poor discriminative power in external validation studies [82, 83], limiting their utility to identify a subgroup of elderly patients at low risk of recurrence. No elderly-specific data are available for the PIT-STOP model which includes age, sex, site of VTE, and D-dimer to generate estimates of recurrent VTE on a continuous scale [77].

Not only assessment of the risk of recurrent VTE but also estimation of the risk of bleeding is difficult in elderly patients. Several scores have been developed to estimate the risk of bleeding in patients on anticoagulants; most of them in cohorts of patients with atrial fibrillation. When applied in elderly patients with VTE, the Outpatient Bleeding Risk Index, ACCP, HAS-BLED, RIETE, HEMORR²HAGES and ATRIA scores showed only poor to moderate discriminative abilities (c-statistics ranging from 0.49 to 0.60) when [84, 85]. The VTE-BLEED score was specifically developed to estimate the risk of bleeding in patients on anticoagulant treatment beyond 6 months of VTE diagnosis [86], but it lacks validation in elderly patients. Seiler et al. have recently proposed a new bleeding score which was derived in a cohort of VTE patients aged 65 year or older and treated with a VKA [87]. Independent risk factors for major bleeding included in the score were previous major bleeding, active cancer, low physical activity, anemia, thrombocytopenia, concomitant antiplatelet drug use, and poor INR control [87]. However, its use cannot be recommended before external validation studies are available, and inclusion of variables specific for VKA treatment may make it less useful for patients on DOACs.

Overall, no validated clinical decision rules are available that help clinicians assess the risk of recurrent VTE and bleeding in elderly patients with VTE. Therefore, shared decision making which incorporates information on consequences of continuing or
stopping anticoagulation, and patient preferences and values should be highly encouraged in elderly patients.
Anticoagulants for extended treatment

When opting for anticoagulant treatment beyond 3 months, the same anticoagulant options are available as for acute treatment and guidelines do not suggest to change anticoagulant after the first 3 months [10, 11]. VKAs, dabigatran, rivaroxaban and apixaban have been specifically evaluated in randomized controlled trials for secondary prevention of VTE in patients without cancer. As in the trials for acute VTE treatment, the proportion of elderly study participants was below 20% in phase III DOAC trials for extended treatment (Table 1). Compared to placebo, active treatment reduced the risk of recurrent VTE and increases the risk of bleeding in both younger and elderly patients (Figure 3 and 4). The RE-MEDY trial is the only study that specifically compared VKA therapy to a DOAC for extended VTE treatment. Overall, dabigatran was non-inferior to VKA therapy for preventing recurrent VTE and associated with a lower risk of major and clinically relevant non-major bleeding (hazard ratio, 0.54; 95% CI, 0.41-0.71) [88]. Only 9% of study participants were 75 years or older, and in those 239 patients no recurrent VTE occurred in either treatment arm. Subgroup analysis for bleeding events were not reported. Rivaroxaban and apixaban are also approved at reduced doses (i.e., 10 mg daily for rivaroxaban and 2.5 mg twice daily for apixaban) during extended VTE treatment, because they are superior to aspirin and placebo, respectively, for secondary prevention of recurrent VTE [89, 90]. Point estimates of risk of recurrent VTE appear to be similar in the subgroup of elderly patients, but a limited number of elderly participants and low event rates preclude judgment on statistical significance (Figure 3). Low-dose aspirin reduces the risk of recurrent VTE by about one third compared to placebo [91]. There is, however, little role for aspirin for extended VTE treatment [92], because
reduced dose rivaroxaban was more efficacious and not associated with a higher risk of bleeding than aspirin in the EINSTEIN CHOICE trial [89].

Based on the few prospective studies reporting on extended anticoagulant treatment for cancer-associated VTE, it seems reasonable to suppose that there is no need to change the choice of anticoagulant after the first 3 months [70-74]. None of these studies reported subgroup analysis by age.

**CONCLUSION**

The incidence of VTE increases with age and elderly patients are at higher risk of VTE-related morbidity and mortality. Even though elderly patients are underrepresented in clinical trials, extrapolation of study results from younger patients to the elderly appears justified for acute VTE treatment and for the choice of anticoagulant agent. Subgroup analyses of phase III DOACs trials indicate that during the acute VTE treatment phase, DOACs are not only associated with a lower risk of bleeding but even appear to be more efficacious than VKAs in preventing recurrent VTE in the elderly.

The most challenging aspect of VTE management in elderly patients is determination of optimal treatment duration. The risk of bleeding increases with age but also several risk factors for recurrent VTE are more frequent in the elderly. Clinical decision rules to help estimating risk of recurrence and bleeding have only limited utility in elderly patients and therefore, shared decision making considering also patient preferences and values is essential in determining individualized treatment duration in the elderly.
ACKNOWLEDGMENT

Tobias Tritschler, Lana A. Castellucci and Grégoire Le Gal are members of the CanVECTOR Network; the Network receives grant funding from the Canadian Institutes of Health Research (CDT-142654). Tobias Tritschler holds an Early Postdoc.Mobility Award from the Swiss National Science Foundation (SNSF P2ZHP3_177999) and a Fellowship Award from the CanVECTOR Network. Lana A. Castellucci is supported by the Heart & Stroke Foundation of Canada National New Investigator and Ontario Clinician Scientist Phase I award programs. Grégoire Le Gal holds an Early Researcher Award from the Province of Ontario, a mid-career clinician scientist award from the Heart and Stroke Foundation of Ontario, and the Chair on the Diagnosis of Venous Thromboembolism, Department of Medicine, University of Ottawa.

AUTHOR CONTRIBUTIONS

Tobias Tritschler performed the meta-analysis and wrote the manuscript. All authors reviewed and revised the manuscript before approving the submission of the final manuscript.
REFERENCES

1. Raskob GE, Angchaisuksiri P, Blanco AN, et al. Thrombosis: a major contributor to global disease burden. Semin Thromb Hemost. 2014; 40: 724-735.

2. Huang W, Goldberg RJ, Anderson FA, et al. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009). Am J Med. 2014; 127: 829-839 e825.

3. Delluc A, Tromeur C, Le Ven F, et al. Current incidence of venous thromboembolism and comparison with 1998: a community-based study in Western France. Thromb Haemost. 2016; 116: 967-974.

4. Anderson DR, Kahn SR, Rodger MA, et al. Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA. 2007; 298: 2743-2753.

5. Carrier M, Righini M, Wells PS, et al. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. J Thromb Haemost. 2010; 8: 1716-1722.

6. Wiener RS, Schwartz LM, Woloshin S. When a test is too good: how CT pulmonary angiograms find pulmonary emboli that do not need to be found. BMJ. 2013; 347: f3368.

7. Tritschler T, Aujesky D. Venous thromboembolism in the elderly: A narrative review. Thromb Res. 2017; 155: 140-147.

8. Mean M, Tritschler T, Limacher A, et al. Association between computed tomography obstruction index and mortality in elderly patients with acute pulmonary embolism: A prospective validation study. PLoS One. 2017; 12: e0179224.

9. Levi M, Hovingh GK, Cannegieter SC, et al. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood. 2008; 111: 4471-4476.
10. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149: 315-352.

11. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020; 41: 543-603.

12. Tritschler T, Kraaijpoel N, Le Gal G, et al. Venous Thromboembolism: Advances in Diagnosis and Treatment. JAMA. 2018; 320: 1583-1594.

13. van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014; 124: 1968-1975.

14. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2019. URL https://www.R-project.org/.

15. Schwarzer G. meta: An R package for meta-analysis. R News. 2007; 7: 40-45.

16. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39: 1330-1393.

17. Moore KT, Krook MA, Vaidyanathan S, et al. Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube. Clin Pharmacol Drug Dev. 2014; 3: 321-327.

18. Song Y, Chang M, Suzuki A, et al. Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults. Clin Ther. 2016; 38: 1674-1685 e1671.

19. Duchin K, Duggal A, Atiee GJ, et al. An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults. Clin Pharmacokinet. 2018; 57: 221-228.
20. Kubitza D, Becka M, Roth A, et al. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor. J Clin Pharmacol. 2013; 53: 249-255.

21. Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2016; 5.

22. Bohula EA, Giugliano RP, Ruff CT, et al. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 2016; 134: 24-36.

23. Mueck W, Lensing AW, Agnelli G, et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011; 50: 675-686.

24. Frost CE, Song Y, Shenker A, et al. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban. Clin Pharmacokinet. 2015; 54: 651-662.

25. Yin OQ, Tetsuya K, Miller R. Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation. Eur J Clin Pharmacol. 2014; 70: 1339-1351.

26. Tomita H, Araki T, Kadokami T, et al. Factors influencing trough and 90-minute plasma dabigatran etexilate concentrations among patients with non-valvular atrial fibrillation. Thromb Res. 2016; 145: 100-106.

27. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014; 129: 764-772.

28. Stöllberger C. Drug interactions with new oral anticoagulants in elderly patients. Expert Rev Clin Pharmacol. 2017; 10: 1191-1202.

29. Trujillo-Santos J, Di Micco P, Dentali F, et al. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. Thromb Haemost. 2017; 117: 382-389.
30. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999; 353: 1386-1389.

31. Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005; 172: 1041-1046.

32. Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014; 311: 2414-2421.

33. Stein PD, Matta F, Steinberger DS, et al. Intracerebral hemorrhage with thrombolytic therapy for acute pulmonary embolism. Am J Med. 2012; 125: 50-56.

34. Stein PD, Matta F. Treatment of unstable pulmonary embolism in the elderly and those with comorbid conditions. Am J Med. 2013; 126: 304-310.

35. Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014; 370: 1402-1411.

36. Kucher N, Boekstegers P, Muller OJ, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation. 2014; 129: 479-486.

37. Piazza G, Hohlfelder B, Jaff MR, et al. A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study. JACC Cardiovasc Interv. 2015; 8: 1382-1392.

38. Enden T, Haig Y, Klow NE, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet. 2012; 379: 31-38.
39. Haig Y, Enden T, Grotta O, et al. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematol. 2016; 3: e64-71.

40. Vedantham S, Goldhaber SZ, Julian JA, et al. Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. N Engl J Med. 2017; 377: 2240-2252.

41. Notten P, Ten Cate-Hoek AJ, Arnoldussen C, et al. Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial. Lancet Haematol. 2020; 7: e40-e49.

42. Tritschler T, Castellucci LA. It’s time for head-to-head trials with direct oral anticoagulants. Thromb Res. 2019; 180: 64-69.

43. Tagalakis V, Patenaude V, Kahn SR, et al. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013; 126: 832 e813-821.

44. Vanassche T, Verhamme P, Wells PS, et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. Thromb Res. 2018; 162: 7-14.

45. Coleman CI, Turpie AGG, Bunz TJ, et al. Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism. Am J Med. 2018; 131: 933-938 e931.

46. Beyer-Westendorf J. What have we learned from real-world NOAC studies in venous thromboembolism treatment? Thromb Res. 2018; 163: 83-91.

47. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361: 2342-2352.

48. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363: 2499-2510.
49. Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366: 1287-1297.

50. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369: 799-808.

51. Buller HR, Decousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369: 1406-1415.

52. Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018.

53. Li A, Garcia DA, Lyman GH, et al. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res. 2019; 173: 158-163.

54. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018; 378: 615-624.

55. Gasparini A, Evans M, Coresh J, et al. Prevalence and recognition of chronic kidney disease in Stockholm healthcare. Nephrol Dial Transplant. 2016; 31: 2086-2094.

56. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003; 41: 1-12.

57. Siontis KC, Zhang X, Eckard A, et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation. 2018; 138: 1519-1529.

58. Ha JT, Neuen BL, Cheng LP, et al. Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med. 2019; 171: 181-189.
59. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ. 2011; 342: d3036.

60. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000; 160: 761-768.

61. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000; 160: 769-774.

62. Schulman S, Lindmarker P, Holmstrom M, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006; 4: 734-742.

63. Spencer FA, Gore JM, Lessard D, et al. Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost. 2008; 100: 780-788.

64. Eischer L, Eichinger S, Kyrle PA. Age at first venous thromboembolism and risk of recurrence: a prospective cohort study. Medicine (Baltimore). 2009; 88: 366-370.

65. Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008; 179: 417-426.

66. Eichinger S, Heinze G, Jandeck LM, et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010; 121: 1630-1636.

67. Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012; 10: 1019-1025.
68. Spencer FA, Gurwitz JH, Schulman S, et al. Venous thromboembolism in older adults: A community-based study. Am J Med. 2014; 127: 530-537 e533.

69. Di Minno MN, Ambrosino P, Dentali F. Safety of warfarin in "high-risk" populations: A meta-analysis of randomized and controlled trials. Thromb Res. 2017; 150: 1-7.

70. Kraaijpoel N, Carrier M. How I treat cancer-associated venous thromboembolism. Blood. 2019; 133: 291-298.

71. Francis CW, Kessler CM, Goldhaber SZ, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost. 2015; 13: 1028-1035.

72. Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, et al. Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study. Thromb Res. 2017; 157: 90-96.

73. Di Nisio M, van Es N, Carrier M, et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost. 2019; 17: 1866-1874.

74. Marshall A, Levine M, Hill C, et al. Treatment of Cancer-Associated Venous Thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomisation of the SELECT-D Trial. (SELECT-D: 12m). J Thromb Haemost. 2020.

75. Khan F, Rahman A, Carrier M, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019; 366: l4363.

76. Kearon C, Iorio A, Palareti G. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. J Thromb Haemost. 2010; 8: 2313-2315.

77. Ensor J, Riley RD, Jowett S, et al. Prediction of risk of recurrence of venous thromboembolism following treatment for a first unprovoked venous thromboembolism:
systematic review, prognostic model and clinical decision rule, and economic evaluation. Health Technol Assess. 2016; 20: i-xxxiii, 1-190.

78. Rodger MA, Le Gal G, Anderson DR, et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ. 2017; 356: j1065.

79. Kahn SR, Shrier I, Julian JA, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med. 2008; 149: 698-707.

80. Kahn SR, Comerota AJ, Cushman M, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2014; 130: 1636-1661.

81. Tritschler T, Limacher A, Mean M, et al. Usefulness of D-Dimer Testing in Predicting Recurrence in Elderly Patients with Unprovoked Venous Thromboembolism. Am J Med. 2017.

82. Tritschler T, Mean M, Limacher A, et al. Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model. Blood. 2015; 126: 1949-1951.

83. Tosetto A, Testa S, Martinelli I, et al. External validation of the DASH prediction rule: a retrospective cohort study. J Thromb Haemost. 2017; 15: 1963-1970.

84. Poli D, Antonucci E, Testa S, et al. The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study. J Thromb Haemost. 2013; 11: 1053-1058.

85. Scherz N, Mean M, Limacher A, et al. Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism. J Thromb Haemost. 2013; 11: 435-443.

86. Klok FA, Hosel V, Clemens A, et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J. 2016; 48: 1369-1376.
87. Seiler E, Limacher A, Mean M, et al. Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation. Thromb Haemost. 2017; 117: 1930-1936.

88. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013; 368: 709-718.

89. Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017; 376: 1211-1222.

90. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368: 699-708.

91. Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012; 367: 1979-1987.

92. Kearon C, Kahn SR. Long-term treatment of venous thromboembolism. Blood. 2020; 135: 317-325.
Table 1. Phase 3 trials of direct oral anticoagulants for acute and extended treatment of VTE in the subgroup of elderly patients

| Study                      | Design            | Proportion of patients >75 y | Intervention                                      | Control                                      | Treatment duration | Primary efficacy outcome | Primary safety outcome |
|----------------------------|-------------------|------------------------------|--------------------------------------------------|----------------------------------------------|-------------------|---------------------------|------------------------|
| **Acute VTE Treatment**    |                   |                              |                                                   |                                              |                   |                           |                        |
| RE-COVER pooled [27, 47]   | Double-blinded    | 529/5,107 (10%)              | LMWH for ≥5 days, then dabigatran 150 mg bid      | LMWH for ≥5 days, then VKA (INR 2-3)         | 6 months          | Recurrent VTE             | Not specified           |
| EINSTEIN pooled [48, 49]   | Open-label        | 1,283/8,281 (15%)            | Rivaroxaban 15 mg bid for 21 days, then 20 mg od | LMWH for ≥5 days, then VKA (INR 2-3)         | 3, 6, or 12 months | Recurrent VTE             | Clinically relevant bleeding a |
| AMPLIFY [50]              | Double-blinded    | 749/5,244 (14%)              | Apixaban 10 mg bid for 7 days, then 5 mg bid      | LMWH for ≥5 days, then VKA (INR 2-3)         | 6 months          | Recurrent VTE             | Major bleeding          |
| Hokusai-VTE [51]          | Double-blinded    | 1,104/8,240 (13%)            | LMWH for ≥5 days, then edoxaban 60 mg od c      | LMWH for ≥5 days, then VKA (INR 2-3)         | 3, 6, or 12 months | Recurrent VTE             | Clinically relevant bleeding a |
| **Extended VTE Treatment**|                   |                              |                                                   |                                              |                   |                           |                        |
| RE-MEDY [88]              | Double-blinded    | 259/2,856 (9%)               | Dabigatran 150 mg bid                             | VKA (INR 2-3)                                | 6-36 months       | Recurrent VTE             | Not specified           |
| RE-SONATE [88]            | Double-blinded    | 452/1,343 (33%)d             | Dabigatran 150 mg bid                             | Placebo                                      | 12 months         | Recurrent VTE             | Not specified           |
| EINSTEIN-EXT [48]         | Open-label        | 188/1,196 (16%)              | Rivaroxaban 20 mg od                              | Placebo                                      | 6-12 months       | Recurrent VTE             | Major bleeding          |
| EINSTEIN-CHOICE [89]      | Double-blinded    | 394/3,365 (12%)              | Rivaroxaban 20 mg od; Rivaroxaban 10 mg od       | Aspirin 100 mg od                            | 6-12 months       | Recurrent VTE             | Major bleeding          |
| AMPLIFY-EXT [90]          | Double-blinded    | 329/2,482 (13%)              | Apixaban 5 mg bid; Apixaban 2.5 mg bid           | Placebo                                      | 12 months         | Recurrent VTE and all-cause death | Major bleeding      |

Abbreviations: bid, twice daily; LMWH, low-molecular-weight heparin; INR, international normalized ratio; od, once daily; VKA, vitamin K antagonist; VTE, venous thromboembolism.

a Clinically relevant bleeding was defined as major bleeding or clinically relevant non-major bleeding.

b Treatment duration at discretion of the physician.

c Dose adjustment (edoxaban 30 mg, od) in patients with a creatinine clearance of 30-50 mL/min or a body weight <60 kg, and in patients receiving concomitant treatment with potent P-glycoprotein inhibitors.
Subgroup analysis for age <65 vs ≥65 years, because subgroup analysis for ≤75 vs >75 years not reported.
Figure 1. Recurrent VTE in DOAC phase 3 trials for acute VTE treatment

A. Association of recurrent VTE with age over 75 years by treatment arm

| Study                      | >75 years Events | >75 years Total | ≤75 years Events | ≤75 years Total | Risk Ratio for Recurrent VTE | RR       | 95%-CI    | Weight |
|----------------------------|------------------|-----------------|------------------|-----------------|------------------------------|----------|-----------|--------|
| **DOAC Treatment Study Arm** |                  |                 |                  |                 |                              |          |           |        |
| RE-COVER I (Dabigatran vs. VKA) | 2 136            | 28              | 1138             | 136             | 0.60                         | [0.14; 2.48] | 2.5%     |
| RE-COVER II (Dabigatran vs. VKA) | 1 117            | 29              | 1162             | 117             | 0.34                         | [0.05; 2.49] | 1.3%     |
| EINSTEIN-DVT (Rivaroxaban vs. VKA) | 4 215            | 32              | 1516             | 215             | 0.88                         | [0.31; 2.47] | 4.6%     |
| EINSTEIN-PE (Rivaroxaban vs. VKA) | 11 441           | 39              | 1978             | 441             | 1.27                         | [0.65; 2.45] | 10.2%    |
| AMPLIFY (Apixaban vs. VKA) | 7 389            | 52              | 2220             | 389             | 0.77                         | [0.35; 1.68] | 7.6%     |
| Hokusai-VTE (Edoxaban vs. VKA) | 14 560           | 116             | 3558             | 560             | 0.77                         | [0.44; 1.33] | 13.8%    |
| **Random effects model** | 39 1858          | 296             | 11572            | 1858            | 0.85                         | [0.61; 1.19] | 40.0%    |

Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.75$

| **VKA Treatment Study Arm** |                  |                 |                  |                 |                              |          |           |        |
|----------------------------|------------------|-----------------|------------------|-----------------|------------------------------|----------|-----------|--------|
| RE-COVER I (Dabigatran vs. VKA) | 3 154            | 24              | 1111             | 154             | 0.90                         | [0.27; 2.96] | 3.5%     |
| RE-COVER II (Dabigatran vs. VKA) | 2 122            | 26              | 1167             | 122             | 0.74                         | [0.18; 3.06] | 2.5%     |
| EINSTEIN-DVT (Rivaroxaban vs. VKA) | 10 225           | 41              | 1493             | 225             | 1.62                         | [0.82; 3.18] | 9.8%     |
| EINSTEIN-PE (Rivaroxaban vs. VKA) | 13 402           | 31              | 2011             | 402             | 2.10                         | [1.11; 3.97] | 10.8%    |
| AMPLIFY (Apixaban vs. VKA) | 13 360           | 58              | 2275             | 360             | 1.42                         | [0.78; 2.56] | 12.2%    |
| Hokusai-VTE (Edoxaban vs. VKA) | 27 544           | 119             | 3578             | 544             | 1.49                         | [0.99; 2.24] | 21.3%    |
| **Random effects model** | 68 1807          | 299             | 11635            | 1807            | 1.51                         | [1.16; 1.96] | 60.0%    |

Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.73$

**Random effects model**

| 107 3665 | 595 23207 | 1.19 [0.95; 1.50] | 100.0% |

Heterogeneity: $I^2 = 13\%$, $\tau^2 = 0.0212$, $p = 0.32$

Residual heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.86$

Test for subgroup differences: $\chi^2 = 6.95$, df = 1 ($p < 0.01$)

Higher in Younger  Higher in Elderly

Abbreviations: CI, confidence interval; RR, risk ratio; VKA, vitamin K antagonist; VTE, venous thromboembolism.
### B. Recurrent VTE by age

| Study          | Intervention | Control | Intervention Events | Control Events | Risk Ratio for Recurrent VTE | RR     | 95%-CI       |
|---------------|--------------|---------|--------------------|----------------|-----------------------------|--------|-------------|
| Age >75 years |              |         |                    |                |                             |        |             |
| RE-COVER      | Dabigatran   | VKA     | 2                  | 136            |                             | 0.75   | [0.13; 4.45]|
| RE-COVER II   | Dabigatran   | VKA     | 1                  | 117            |                             | 0.52   | [0.05; 5.67]|
| EINSTEIN-DVT  | Rivaroxaban  | VKA     | 4                  | 215            |                             | 0.42   | [0.13; 1.31]|
| EINSTEIN-PE   | Rivaroxaban  | VKA     | 11                 | 441            |                             | 0.77   | [0.35; 1.70]|
| AMPLIFY       | Apixaban     | VKA     | 7                  | 389            |                             | 0.50   | [0.20; 1.24]|
| Hokusai-VTE   | Edoxaban     | VKA     | 14                 | 560            |                             | 0.50   | [0.27; 0.95]|
|               |              |         | 39                 | 1858           |                             | 0.56   | [0.38; 0.82]|

Random effects model

Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.95$

| Age ≤75 years |              |         |                    |                |                             |        |             |
|---------------|--------------|---------|--------------------|----------------|-----------------------------|--------|-------------|
| RE-COVER      | Dabigatran   | VKA     | 28                 | 1138           |                             | 1.14   | [0.66; 1.95]|
| RE-COVER II   | Dabigatran   | VKA     | 29                 | 1162           |                             | 1.12   | [0.66; 1.89]|
| EINSTEIN-DVT  | Rivaroxaban  | VKA     | 32                 | 1516           |                             | 0.77   | [0.49; 1.21]|
| EINSTEIN-PE   | Rivaroxaban  | VKA     | 39                 | 1978           |                             | 1.28   | [0.80; 2.04]|
| AMPLIFY       | Apixaban     | VKA     | 52                 | 2220           |                             | 0.92   | [0.63; 1.33]|
| Hokusai-VTE   | Edoxaban     | VKA     | 116                | 3558           |                             | 0.98   | [0.76; 1.26]|
|               |              |         | 296                | 11572          |                             | 0.99   | [0.85; 1.17]|

Random effects model

Heterogeneity: $I^2 = 3\%$, $\tau^2 = 0.0026$, $p = 0.41$

Test for subgroup differences: $\chi^2 = 7.26$, df = 1 ($p < 0.01$)

---

Abbreviations: CI, confidence interval; DOAC, direct oral anticoagulant; RR, risk ratio; VKA, vitamin K antagonist; VTE, venous thromboembolism.
Figure 2. Major bleeding in DOAC phase 3 trials for acute VTE treatment

A. Association of major bleeding with age over 75 years by treatment arm

| Study                              | >75 years Events | Total | ≤75 years Events | Total | Risk Ratio for Major Bleeding | RR     | 95%-CI   | Weight |
|------------------------------------|------------------|-------|------------------|-------|------------------------------|--------|---------|--------|
| DOAC Treatment Study Arm           |                  |       |                  |       |                              |        |         |        |
| RE-COVER pooled (Dabigatran vs. VKA)| 8 231            | 16    | 2225             |       | 4.82 [2.08; 11.13]           | 7.1%   |         |        |
| EINSTEIN-DVT (Rivaroxaban vs. VKA) | 3 215            | 9     | 1503             |       | 2.33 [0.64; 8.54]            | 3.0%   |         |        |
| EINSTEIN-PE (Rivaroxaban vs. VKA)  | 5 440            | 21    | 1972             |       | 1.07 [0.40; 2.81]            | 5.3%   |         |        |
| AMPLIFY (Apixaban vs. VKA)         | 4 398            | 11    | 2278             |       | 2.08 [0.67; 6.50]            | 3.8%   |         |        |
| Hokusai-VTE (Edoxaban vs. VKA)     | 17 560           | 39    | 3558             |       | 2.77 [1.58; 4.86]            | 15.8%  |         |        |
| Random effects model               | 37 1844          | 96    | 11536            |       | 2.56 [1.76; 3.74]            | 35.0%  |         |        |
| Heterogeneity: $I^2 = 29\%$, $\tau^2 = 0$, $p = 0.23$ |                  |       |                  |       |                              |        |         |        |
| VKA Treatment Study Arm            |                  |       |                  |       |                              |        |         |        |
| RE-COVER pooled (Dabigatran vs. VKA)| 10 262           | 30    | 2200             |       | 2.80 [1.38; 5.66]            | 10.1%  |         |        |
| EINSTEIN-DVT (Rivaroxaban vs. VKA) | 5 223            | 15    | 1488             |       | 2.22 [0.82; 6.06]            | 5.0%   |         |        |
| EINSTEIN-PE (Rivaroxaban vs. VKA)  | 23 401           | 29    | 2004             |       | 3.96 [2.32; 6.78]            | 17.3%  |         |        |
| AMPLIFY (Apixaban vs. VKA)         | 16 370           | 33    | 2319             |       | 3.04 [1.69; 5.47]            | 14.5%  |         |        |
| Hokusai-VTE (Edoxaban vs. VKA)     | 19 544           | 47    | 3578             |       | 2.66 [1.57; 4.50]            | 18.1%  |         |        |
| Random effects model               | 73 1800          | 154   | 11589            |       | 3.03 [2.30; 4.00]            | 65.0%  |         |        |
| Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.81$ |                  |       |                  |       |                              |        |         |        |
| Random effects model               | 110 3644         | 250   | 23125            |       | 2.86 [2.28; 3.57]            | 100.0% |         |        |
| Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.56$ |                  |       |                  |       |                              |        |         |        |
| Residual heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.51$ |                  |       |                  |       |                              |        |         |        |
| Test for subgroup differences: $\chi^2 = 0.49$, df = 1 ($p = 0.48$) |                  |       |                  |       |                              |        |         |        |

Abbreviations: CI, confidence interval; RR, risk ratio; VKA, vitamin K antagonist.
### B. Major bleeding by age

| Study              | Intervention | Control | Risk Ratio for Major Bleeding | RR   | 95%-CI   |
|--------------------|--------------|---------|-------------------------------|------|---------|
| **Age >75 years**  |              |         |                               |      |         |
| RE-COVER pooled    | Dabigatran   | VKA     | 8 231 10 262                  | 0.91 | [0.36; 2.26] |
| EINSTEIN-DVT       | Rivaroxaban  | VKA     | 3 215 5 223                   | 0.62 | [0.15; 2.57] |
| EINSTEIN-PE        | Rivaroxaban  | VKA     | 5 440 23 401                  | 0.20 | [0.08; 0.52] |
| AMPLIFY            | Apixaban     | VKA     | 4 398 16 370                  | 0.23 | [0.08; 0.69] |
| Hokusai-VTE        | Edoxaban     | VKA     | 17 560 19 544                 | 0.87 | [0.46; 1.65] |
| Random effects model|             |         |                               | 0.51 | [0.30; 0.85] |
| Heterogeneity: $I^2 = 60\%$, $t^2 = 0.1209$, $p = 0.04$ | | | | | |
| **Age ≤75 years**  |              |         |                               |      |         |
| RE-COVER pooled    | Dabigatran   | VKA     | 16 2225 30 2200               | 0.53 | [0.29; 0.96] |
| EINSTEIN-DVT       | Rivaroxaban  | VKA     | 9 1503 15 1488                | 0.59 | [0.26; 1.35] |
| EINSTEIN-PE        | Rivaroxaban  | VKA     | 21 1972 29 2004               | 0.74 | [0.42; 1.29] |
| AMPLIFY            | Apixaban     | VKA     | 11 2278 33 2319               | 0.34 | [0.17; 0.67] |
| Hokusai-VTE        | Edoxaban     | VKA     | 39 3558 47 3578               | 0.83 | [0.55; 1.27] |
| Random effects model|             |         |                               | 0.60 | [0.40; 0.90] |
| Heterogeneity: $I^2 = 28\%$, $t^2 = 0.1209$, $p = 0.24$ | | | | | |
| Heterogeneity: $I^2 = 44\%$, $t^2 = 0.1001$, $p = 0.07$ | | | | | |
| Test for subgroup differences: $\chi^2 = 0.25$, df = 1 ($p = 0.61$) | | | | | |

Abbreviations: CI, confidence interval; DOAC, direct oral anticoagulant; RR, risk ratio; VKA, vitamin K antagonist.
Figure 3. Primary efficacy outcome in DOAC phase 3 trials for extended VTE treatment by age

| Study         | Intervention | Control  | Age  | Risk Ratio for Primary Efficacy Outcome | Intervention | Control |
|---------------|--------------|----------|------|-----------------------------------------|--------------|---------|
|               |              |          |      |                                         | Events       | Total    |
|               |              |          |      |                                         | Events       | Total    |
| Placebo       | Dabigatran   | Placebo  | >65 y|                                         | 1            | 237      |
|               |              |          |      |                                         | 19           | 215      |
|               |              |          |      |                                         | 0.05         | [0.01; 0.35]|
|               | Dabigatran   | Placebo  | <65 y|                                         | 2            | 444      |
|               |              |          |      |                                         | 18           | 447      |
|               |              |          |      |                                         | 0.11         | [0.03; 0.48]|
|               | Rivaroxaban 20 mg | Placebo  | >75 y|                                         | 1            | 89       |
|               |              |          |      |                                         | 11           | 99       |
|               |              |          |      |                                         | 0.10         | [0.01; 0.77]|
|               | Rivaroxaban 20 mg | Placebo  | ≤75 y|                                         | 7            | 513      |
|               |              |          |      |                                         | 31           | 495      |
|               |              |          |      |                                         | 0.22         | [0.10; 0.49]|
|               | Apixaban 5 mg | Placebo  | >75 y|                                         | 4            | 109      |
|               |              |          |      |                                         | 14           | 109      |
|               |              |          |      |                                         | 0.29         | [0.10; 0.84]|
|               | Apixaban 5 mg | Placebo  | ≤75 y|                                         | 30           | 704      |
|               |              |          |      |                                         | 82           | 720      |
|               |              |          |      |                                         | 0.37         | [0.25; 0.56]|
|               | Apixaban 2.5 mg | Placebo  | >75 y|                                         | 6            | 111      |
|               |              |          |      |                                         | 14           | 109      |
|               |              |          |      |                                         | 0.42         | [0.17; 1.06]|
|               | Apixaban 2.5 mg | Placebo  | ≤75 y|                                         | 26           | 729      |
|               |              |          |      |                                         | 82           | 720      |
|               |              |          |      |                                         | 0.31         | [0.20; 0.48]|

Active Control

| Study         | Intervention | Control   | Age  | Risk Ratio for Primary Efficacy Outcome | Intervention | Control |
|---------------|--------------|-----------|------|-----------------------------------------|--------------|---------|
|               |              |           |      |                                         | Events       | Total    |
|               |              |           |      |                                         | Events       | Total    |
| RE-MEDY       | Dabigatran   | VKA       | >75 y|                                         | 0            | 140      |
|               |              |           |      |                                         | 0            | 119      |
|               | Dabigatran   | VKA       | ≤75 y|                                         | 26           | 1290     |
|               |              |           |      |                                         | 18           | 1307     |
|               |              |           |      |                                         | 1.46         | [0.81; 2.66]|
| EINSTEIN-CHOICE | Rivaroxaban 20 mg | Aspirin  | >75 y|                                         | 1            | 115      |
|               |              |           |      |                                         | 6            | 146      |
| EINSTEIN-CHOICE | Rivaroxaban 20 mg | Aspirin  | ≤75 y|                                         | 16           | 992      |
|               |              |           |      |                                         | 44           | 985      |
|               |              |           |      |                                         | 0.36         | [0.21; 0.64]|
| EINSTEIN-CHOICE | Rivaroxaban 10 mg | Aspirin  | >75 y|                                         | 4            | 133      |
|               |              |           |      |                                         | 6            | 146      |
| EINSTEIN-CHOICE | Rivaroxaban 10 mg | Aspirin  | ≤75 y|                                         | 9            | 994      |
|               |              |           |      |                                         | 44           | 985      |
|               |              |           |      |                                         | 0.20         | [0.10; 0.41]|
| EINSTEIN-CHOICE | Rivaroxaban 20 mg | Rivaroxaban 10 mg | >75 y|                                         | 1            | 115      |
|               |              |           |      |                                         | 6            | 133      |
| EINSTEIN-CHOICE | Rivaroxaban 20 mg | Rivaroxaban 10 mg | ≤75 y|                                         | 16           | 992      |
|               |              |           |      |                                         | 9            | 994      |
|               |              |           |      |                                         | 1.78         | [0.79; 4.01]|
| AMPLIFY-EXT   | Apixaban 5 mg | Apixaban 2.5 mg | >75 y|                                         | 4            | 109      |
|               |              |           |      |                                         | 6            | 111      |
|               |              |           |      |                                         | 0.68         | [0.20; 2.34]|
| AMPLIFY-EXT   | Apixaban 5 mg | Apixaban 2.5 mg | ≤75 y|                                         | 30           | 704      |
|               |              |           |      |                                         | 26           | 729      |
|               |              |           |      |                                         | 1.19         | [0.71; 2.00]|

Abbreviations: CI, confidence interval; RR, risk ratio; VKA, vitamin K antagonist.
**Figure 4. Primary safety outcome in DOAC phase 3 trials for extended VTE treatment by age**

| Study          | Intervention          | Control            | Age     | Risk Ratio for Primary Safety Outcome | Intervention Events | Total | Control Events | Total | RR   | 95%-CI      |
|----------------|-----------------------|--------------------|---------|---------------------------------------|---------------------|-------|----------------|-------|------|------------|
| **Placebo**    |                       |                    |         |                                       |                     |       |                |       |      |            |
| EINSTEIN-EXT   | Rivaroxaban 20 mg     | Placebo            | >75 y   |                                       | 7                   | 88    | 3              | 98    | 2.60 | [0.69; 9.74]|
|                |                       |                    | ≤75 y   |                                       | 29                  | 510   | 3              | 492   | 9.33 | [2.86; 30.42]|
| AMPLIFY-EXT    | Apixaban 5 mg         | Placebo            | >75 y   |                                       | 5                   | 108   | 1              | 109   | 5.05 | [0.60; 42.48]|
|                |                       |                    | ≤75 y   |                                       | 30                  | 703   | 21             | 717   | 1.46 | [0.84; 2.52] |
| AMPLIFY-EXT    | Apixaban 2.5 mg       | Placebo            | >75 y   |                                       | 7                   | 111   | 1              | 109   | 6.67 | [0.86; 54.94]|
|                |                       |                    | ≤75 y   |                                       | 20                  | 729   | 21             | 717   | 0.94 | [0.51; 1.71] |
| **Aspirin or Reduced Dose DOAC** |                       |                    |         |                                       |                     |       |                |       |      |            |
| EINSTEIN-CHOICE | Rivaroxaban 20 mg     | Aspirin            | >75 y   |                                       | 5                   | 115   | 8              | 146   | 0.79 | [0.27; 2.36] |
|                |                       |                    | ≤75 y   |                                       | 31                  | 992   | 15             | 985   | 2.05 | [1.11; 3.78] |
| EINSTEIN-CHOICE | Rivaroxaban 10 mg     | Aspirin            | >75 y   |                                       | 2                   | 133   | 8              | 146   | 0.27 | [0.06; 1.27] |
|                |                       |                    | ≤75 y   |                                       | 25                  | 994   | 15             | 985   | 1.65 | [0.88; 3.11] |
| EINSTEIN-CHOICE | Rivaroxaban 20 mg     | Rivaroxaban 10 mg  | >75 y   |                                       | 5                   | 115   | 2              | 133   | 2.89 | [0.57; 14.62]|
|                |                       |                    | ≤75 y   |                                       | 31                  | 992   | 25             | 994   | 1.24 | [0.74; 2.09] |
| AMPLIFY-EXT    | Apixaban 5 mg         | Apixaban 2.5 mg    | >75 y   |                                       | 5                   | 108   | 7              | 111   | 0.73 | [0.24; 2.24] |
|                |                       |                    | ≤75 y   |                                       | 30                  | 703   | 20             | 729   | 1.56 | [0.89; 2.71] |

Abbreviations: CI, confidence interval; DOAC, direct oral anticoagulant; RR, risk ratio.